Astellas Pharma EBITDA vs. Net Income
Astellas Pharma Net Income vs. EBITDA Fundamental Analysis
Cross-company financial ratios help determine Astellas Pharma's valuation standing. Astellas Pharma holds the top spot in ebitda across its competitive set. It also holds the top spot in net income across its competitive set at roughly 0.08 Net Income per unit of EBITDA. Astellas Pharma carries a 11.99 x EBITDA-to-Net Income ratio. Based on recent performance metrics, EBITDA is expected to decrease significantly. In the prior fiscal year, EBITDA was reported at 222.19 Billion. Peer multiple models assess Astellas Pharma's valuation efficiency.Astellas Net Income vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Astellas Pharma |
| = | 608.5 B |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Astellas Pharma |
| = | 50.75 B |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Astellas Net Income Comparison
Astellas Pharma is currently under evaluation in net income across its competitive set.
Astellas Pharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Astellas Pharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Astellas Pharma will eventually generate negative long term returns. The profitability progress is the general direction of Astellas Pharma's change in net profit over the period of time. It can combine multiple indicators of Astellas Pharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Operating Income | 36.2 B | 34.4 B | |
| Net Income From Continuing Ops | 45.7 B | 43.4 B | |
| Income Before Tax | 28.1 B | 26.7 B | |
| Total Other Income Expense Net | -38.5 B | -40.4 B | |
| Net Income Applicable To Common Shares | 142.7 B | 179.2 B | |
| Net Income | 58.4 B | 55.4 B | |
| Income Tax Expense | 29.5 B | 35.9 B | |
| Net Interest Income | -8.8 B | -8.4 B | |
| Interest Income | 7.1 B | 7.6 B | |
| Change To Netincome | 18 B | 18.9 B |
Astellas Profitability Driver Comparison
Profitability drivers for Astellas Pharma are the operational and financial factors that most directly influence its earnings. Investors must be prepared for unexpected events that can disrupt market behavior and cause sudden, significant shifts in Astellas Pharma's profit margins and valuations.
Earnings per Share Projection vs Actual
Use Astellas Pharma in pair-trading
Pair trading with Astellas Pharma can help investors hedge some company-specific exposure by balancing a long view with an offsetting position. The key question is whether the second leg adds real hedge value instead of just creating a more complex version of the same risk.
Astellas Pharma Pair Trading
Astellas Pharma Pair Trading Analysis
When executing tax-loss harvesting on Astellas Pharma, the goal is to sell at a loss and immediately redeploy proceeds into a sufficiently different but highly correlated asset. This approach maintains Astellas Pharma's risk contribution to the portfolio while generating a realized tax loss.
Rolling correlation analysis for Astellas Pharma shows how its relationship with other instruments evolves over time. Correlations that spike toward +1 during market stress suggest that Astellas Pharma's diversification benefits may disappear precisely when they are most needed.
Correlation analysis and pair evaluation for Astellas Pharma can support hedging context. The approach can be applied within sectors or across broader universes.Use Investing Themes to Complement your Astellas Pharma position
Using Astellas Pharma inside a theme workflow gives investors a structured way to compare related stocks, funds, ETFs, and crypto assets before allocating capital. The practical benefit is that the selected idea can be tuned either for higher upside or for tighter risk control.
Did You Try This Idea?
Run Emerging Markets ETFs Thematic Idea Now
Emerging Markets ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Emerging Markets ETFs theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Emerging Markets ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
More Resources for Astellas Stock Analysis
Other Information on Investing in Astellas Stock
A projection view for Astellas Pharma starts with historical financial statements. Core documents include the income statement, balance sheet, and cash-flow statement.